With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

Merck (MRK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Investors are ramping up AI-related M&A to secure cutting-edge capabilities and market-beating returns, but high valuations and open-source ...

Q4 2024 Earnings Call Transcript February 28, 2025 Gem Hopkins: Good morning and good afternoon, everyone. Thank you for ...

Eisai plans to lay off 121 employees in the U.S. A former deputy director of China's drug agency is under investigation by anti-corruption authorities. | Eisai plans to lay off 121 employees in the U.

When Silence Therapeutics unveiled its latest zerlasiran phase 2 data at the American Heart Association (AHA) conference in ...

The Company's cash guidance is now extended into 2027 Company to host conference call and webcast today at 8 a.m. EST 1 p.m. GMT Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company") ...

In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Viking advances VK2735 with a phase 2a study targeting results in H2'25. Phase 3 begins in Q2'25, fueling progress and ...

That includes GSK – which licensed a B7-H3 ADC from Hansoh Pharma in a $1.5 billion-plus deal signed last December – and MacroGenics, which has a candidate called vobramitamab duocarmazine ...